BSE filing, BSE: 544023. Summary written from the filing by ALFA Finder's alert engine.
Kalyani Cast-Tech Ltd: key numbers
- Share price
- ₹1,152.90
- Market cap
- ₹827.8 Cr
- Revenue (annual)
- ₹149.9 Cr
- Net profit (annual)
- ₹17.08 Cr
- P/E (TTM)
- 48.5×Sector 52.2×
- Promoter holding
- 59.48%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kalyani Cast-Tech Ltd
All →Kalyani Cast-Tech Other Announcement
Kalyani Cast-Tech Ltd submitted its shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI Regulation 31(1)(b).
Kalyani Cast-Tech Annual General Meeting
Kalyani Cast Tech Limited held its 14th Annual General Meeting on September 30, 2026. The meeting covered the adoption of financial statements and routine business resolutions.
Kalyani Cast-Tech Capital Structure Change
Kalyani Cast-Tech allotted 323,123 convertible warrants at ₹582 each, raising ₹18.81 Crore from seven investors on a preferential basis. Warrants convert into equity shares within 18 months.
- Value
- ₹18.81 Cr
Kalyani Cast-Tech Business Update
Kalyani Cast-Tech Ltd rescheduled the inauguration of its Gati Shakti Cargo Terminal, salt train flagging, and ICD foundation laying to September 15, 2026.
Kalyani Cast-Tech Capacity Expansion
Kalyani Cast-Tech to inaugurate its Gati Shakti Cargo Terminal and lay the ICD foundation stone at Bhachau, Kutch. The event marks expansion of its rail-linked logistics infrastructure.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast Tech received CBIC approval for an Inland Container Depot at Shivlakha, Kutch. The ICD anchors its integrated rail, logistics and manufacturing platform at Shivlakha.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.
KFIN Technologies Regulatory Approval
KFin Technologies' Thai subsidiary received a Foreign Business License from Thailand's Ministry of Commerce. The license enables the subsidiary to conduct permitted business activities under local law.